Hyperphosphatemia Drugs

Global Hyperphosphatemia Drugs Market to Reach US$5.6 Billion by 2030

The global market for Hyperphosphatemia Drugs estimated at US$4.2 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Sevelamer, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Calcium-based Phosphate Binders segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.9% CAGR

The Hyperphosphatemia Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Key Trends and Drivers

Hyperphosphatemia, characterized by abnormally high phosphate levels in the blood, typically occurs in patients with chronic kidney disease (CKD) or those on dialysis. Managing phosphate levels is crucial as hyperphosphatemia can lead to serious conditions like cardiovascular disease and bone disorders. The primary treatment involves the use of phosphate binders—drugs that bind phosphate in the digestive tract to prevent its absorption. These binders include calcium-based compounds, such as calcium carbonate and calcium acetate, and non-calcium-based agents like sevelamer and lanthanum carbonate, which are preferred due to their lower risk of causing hypercalcemia. The choice of binder often depends on the patient`s overall health, phosphate levels, and existing treatment regimen.

In addition to phosphate binders, dietary management is an integral part of controlling phosphorus levels. However, with the limitations of diet alone to maintain safe phosphorus levels in advanced CKD or dialysis patients, there is a continuous demand for more effective and convenient therapeutic options. Recent advances focus on new formulations and combinations of existing phosphate binders, improving patient adherence and minimizing side effects. There is also growing interest in developing drugs that target the hormonal regulation of phosphate metabolism, offering potential new mechanisms of action beyond binding dietary phosphate.

The growth in the hyperphosphatemia drugs market is driven by several factors, including the increasing prevalence of chronic kidney disease globally, due in part to rising rates of diabetes and hypertension. Advances in dialysis treatment increasing the longevity of CKD patients also contribute to a growing patient population requiring long-term management of phosphate levels. Furthermore, the development of new and more effective phosphate binders and the increasing awareness of the complications associated with hyperphosphatemia stimulate demand for these drugs. Market expansion is also supported by healthcare policies improving access to treatment and the growing focus on enhancing the quality of life for patients with chronic conditions.

SCOPE OF STUDY:

The report analyzes the Hyperphosphatemia Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate, Other Products); Dosage Form (Tablets Form, Syrups Form, Capsules Form); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 51 Featured) -

• Akebia Therapeutics, Inc.
• Alebund Pharmaceuticals
• Ardelyx, Inc
• Chugai Pharmaceutical Co., Ltd.
• CSL Limited
• Dr. Paul Lohmann GmbH & Co. KGaA
• Fresenius Medical Care North America
• Kabir Lifesciences
• Kissei Pharmaceutical Co., Ltd
• Kyowa Kirin Co., Ltd.
• Macsen Laboratories
• Sanofi S.A.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Torii Pharmaceutical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.